Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graftinge Among Patients with Unprotected Left Main Coronary Artery Disease in the New-Generation Drug-Eluting Stents Era (From the CREDO-Kyoto PCI/CABG Registry Cohort-3)
Section snippets
Methods
The Coronary Revascularization Demonstrating Outcome Study in Kyoto (CREDO-Kyoto) PCI/CABG registry Cohort-3 is a physician-initiated, noncompany-sponsored, multicenter registry enrolling consecutive patients who underwent first coronary revascularization with PCI or isolated CABG without combined non-coronary surgery among 22 Japanese centers between January 2011 and December 2013 (Supplemental Appendix). The relevant ethics committees in all the participating centers approved the study
Results
Among the 855 current study patients, 383 patients (45%) underwent PCI, while 472 patients (55%) underwent CABG (Figure 1). Patients in the PCI group were significantly older and more often had severe frailty and peripheral vascular disease than those in the CABG group, whereas patients in the CABG group had higher prevalence of chronic obstructive pulmonary disease than those in the PCI group (Table 1). Regarding angiographic and procedural characteristics, patients with isolated LMCA or
Discussion
The main findings of this study comparing PCI with CABG in patients with ULMCAD in the new-generation DES era were as follows; (1) In the present study population reflecting real-world clinical practice in Japan between 2011 and 2013, 45% of patients with ULMCAD underwent PCI as the first coronary revascularization, and selection of coronary revascularization modalities appeared to be mainly based on the extent of coronary artery disease with isolated LMCA or LMCA+1-VD almost exclusively
Author contribution
Ko Yamamoto: Methodology, Formal analysis, Investigation, Data curation, Writing - Original Draft. Hiroki Shiomi: Methodology, Investigation, Data curation, Writing-Review and Editing, Supervision, Project administration. Takeshi Morimoto: Methodology, Formal analysis, Writing-Review and Editing, Supervision. Kazushige Kadota: Investigation, Resources. Tomohisa Tada: Investigation, Resources. Yasuaki Takeji: Investigation, Data curation. Yukiko Matsumura-Nakano: Investigation, Data curation.
Declaration of interests
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgments
We appreciate the support and collaboration of the co-investigators participating in the CREDO-Kyoto PCI/CABG Registry Cohort-3. We are indebted to the clinical research coordinators for data collection.
References (22)
- et al.
Left main coronary artery disease
J Am Coll Cardiol
(2016) - et al.
Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial
Lancet
(2019) - et al.
Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial
Lancet
(2020) - et al.
Coronary artery bypass surgery improves outcomes in patients with diabetes and left ventricular dysfunction
J Am Coll Cardiol
(2018) - et al.
Stroke rates following surgical versus percutaneous coronary revascularization
J Am Coll Cardiol
(2018) - et al.
Temporal trends in revascularization strategy and outcomes in left main coronary artery stenosis data from the asan medical center-left main revascularization registry
Circ Cardiovasc Interv
(2015) - et al.
Ten-year outcomes after drug-eluting stents versus coronary artery bypass grafting for left main coronary disease: extended follow-up of the PRECOMBAT trial
Circulation
(2020) - et al.
Five-year outcomes after PCI or CABG for left main coronary disease
N Engl J Med
(2019) - et al.
2018 ESC/EACTS Guidelines on myocardial revascularization
Eur Heart J
(2018) - et al.
2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
Circulation
(2014)
Long-term outcomes in patients with severely reduced left ventricular ejection fraction undergoing percutaneous coronary intervention vs coronary artery bypass grafting
JAMA Cardiol
Cited by (8)
Coronary Artery Disease Without Standard Cardiovascular Risk Factors
2022, American Journal of CardiologyCitation Excerpt :Current smoking was defined as regularly smoking within the last 1 month before the index hospitalization. Other definitions for baseline characteristics were described previously.7,8 The primary outcome measure of this study was all-cause death.
Effect of Polypharmacy on Long-Term Mortality After Percutaneous Coronary Intervention
2021, American Journal of CardiologyCitation Excerpt :We categorized the medications by drug classes according to the Anatomical Therapeutic Chemical classification system.11 Definitions for baseline characteristics were described previously.9,10 The primary outcome measure was all-cause death.
Percutaneous Coronary Revascularization: JACC Historical Breakthroughs in Perspective
2021, Journal of the American College of CardiologyCitation Excerpt :The score is derived using data from the SYNTAX trial, which used the first-generation paclitaxel-eluting stent, and although this is a major limitation, these are the only 10-year outcome data available to date. Recently the score was validated in the CREDO-Kyoto PCI/CABG registry cohort 3 (116,117), in which 90.3% of PCIs were performed using newer-generation DES, supporting the utility of decision making using the SYNTAX score II 2020 in contemporary practice. Its availability on smartphones and other devices renders its use more accessible and applicable than ever.
Sex Differences in Clinical Outcomes After Percutaneous Coronary Intervention
2023, Circulation JournalLong-term prognosis of culotte versus different crush strategies in management of unprotected left main bifurcation coronary lesions: A meta-analysis
2022, Journal of the Pakistan Medical AssociationTrends in Clinical Practice and Outcomes After Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery
2022, Journal of the American Heart Association
Disclosures: Dr. Shiomi reports honoraria from Abbott Vascular, and Boston Scientific. Dr. Morimoto reports honoraria from Bayer and Kowa, and expert witness from Boston Scientific and Sanofi. Dr. Ehara reports honoraria from Abbott Vascular, Bayer, Boston Scientific, Medtronic, and Terumo. Dr. Furukawa reports honoraria from Bayer, Kowa, and Sanofi. Dr. Nakagawa reports research grant from Abbott Vascular and Boston Scientific, and honoraria from Abbott Vascular, Bayer, and Boston Scientific. Dr. Kimura reports honoraria from Abbott Vascular, Astellas, AstraZeneca, Bayer, Boston Scientific, Kowa, and Sanofi. The remaining authors have nothing to disclose.
Funding: This work was supported by an educational grant from the Research Institute for Production Development (Kyoto, Japan).